Which medications in the drug class Nonnucleoside Reverse Transcriptase Inhibitors are used in the treatment of Pediatric HIV Infection?

Updated: Mar 05, 2020
  • Author: Delia M Rivera, MD; Chief Editor: Russell W Steele, MD  more...
  • Print

Nonnucleoside Reverse Transcriptase Inhibitors

NNRTIs inhibit both DNA-directed and RNA-directed polymerase functions of HIV-1 reverse transcriptase. The different sites of action of nonnucleoside and nucleoside inhibitors suggest potential synergistic effects of these agents and their potential activity against nucleoside-resistant HIV strains.

Efavirenz (DMP-266, EFV, Sustiva)

Efavirenz is used only in combination regimens. It is approved by the FDA for children aged 3 months or older who weigh at least 3.5 kg.

Nevirapine (NVP, Viramune, Viramune XR)

Nevirapine is indicated for use in combination with other ARDs for treatment of HIV-1 infection. It is approved by the FDA in children from infancy (aged ≥ 15 days) onward. The extended-release tablet is approved for use in children aged ≥ 6 years.

Rilpivirine (Edurant)

NNRTI indicated in combination with other ARTs for treatment of HIV-1 infection in treatment-naïve adolescents aged 12-17 years who weigh at least 35 kg with HIV-1 RNA ≤ 100,000 copies/mL.

Etravirine (Intelence)

Indicated in combination with other antiretroviral agents (ART) for treatment of HIV-1 infection in ART-experienced patients with evidence of viral replication and HIV-1 strains resistant to a NNRTIs and other antiretroviral agents in children aged 2 years or older and weigh at least 10 kg.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!